Deng and colleagues recently developed a novel immune cell receptor (ICR) structure, designated TB15, by fusing the extracellular domain of TGF‐β receptor II (TGF‐βRII) with the intracellular domain of IL‐15 receptor α (IL‐15Rα).[105] TB15‐modified CAR‐T cells exhibited remarkable anti‐tumor activity in environments characterized by high levels of TGF‐β, effectively inhibiting TGF‐β signaling while simultaneously activating IL‐15‐mediated stimulation. The gene discussed is IL15; the disease is neoplasm.